Jazz Pharmaceuticals price target raised to $235 from $170 at Wells Fargo

Wells Fargo raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $235 from $170 and keeps an Overweight rating on the shares. The firm sees zanidatamab’s gastroesophageal adenocarcinoma read out supporting it as new standard of care in GEA. Zani’s success in GEA may be a readthrough to breast cancer, and Wells sees an unadjusted peak opportunity of about $3B in both indications. Data is expected in Q1 2026, potentially at ASCO GI, the firm adds.